Research programme: cell therapies - Artisan Bio/Takeda
Latest Information Update: 28 Feb 2024
At a glance
- Originator Artisan Bio; Takeda
- Developer Artisan Bio
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 14 Mar 2023 Artisan Bio extends the cell therapy research collaboration with Takeda using Artisan's genome editing platform
- 20 Jan 2020 Artisan Bio and Takeda collaborate for the research and development of cell therapy products for the treatment of unknown indication